Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV
January 04, 2023 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist Lugano, Switzerland, January 4, 2023 - Helsinn Group (“Helsinn”), a fully integrated...
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
November 29, 2022 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global...
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region
November 28, 2022 06:00 ET
|
Helsinn Healthcare S.A.
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a...
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy
October 18, 2022 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting
September 21, 2022 08:34 ET
|
Helsinn Healthcare S.A.
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both clinical trials and real-world settings will be presentedHelsinn...
Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care
September 08, 2022 08:00 ET
|
Helsinn Healthcare S.A.
Dr. Rushil V. Patel named 2022 recipient of The Conquer Cancer – Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care Lugano, Switzerland, September 8, 2022 - Helsinn Group...
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
September 01, 2022 05:08 ET
|
Helsinn Healthcare S.A.
Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East* Lugano, Switzerland, September 1, 2022 –...
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer
August 08, 2022 04:07 ET
|
Helsinn Healthcare S.A.
Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer Lugano, Switzerland, August 8, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global...
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022
June 02, 2022 08:30 ET
|
Helsinn Healthcare S.A.
New data on Helsinn’s oncology pipeline presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022 Lugano, Switzerland, June 02, 2022 - Helsinn Group (“Helsinn”), a fully...
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy
May 25, 2022 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.),...